Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) Q1 2026 Earnings

ENSC·Reported May 15, 2026·After market close

Ensysce Biosciences, Inc. reported Q1 2026 revenue of $961.0K (-27.2% YoY), missed analyst consensus of $1.0M by $39.0K. Diluted EPS came in at $-0.52 (+62.6% YoY).

Revenue
$961.0Kmissed by $39.0K
Consensus: $1.0M
Diluted EPS
$-0.52met estimate
Consensus: $-0.52
SEC

SEC Filings

Earnings release8-K · 0001493152-26-023810
Quarterly report10-Q · 0001493152-26-023811

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Ensysce Biosciences, Inc.'s Q1 2026 earnings report.

Ensysce Biosciences, Inc. (ENSC) reported Q1 2026 earnings on May 15, 2026 after market close.

Ensysce Biosciences, Inc. reported revenue of $961.0K and diluted EPS of $-0.52 for Q1 2026.

Revenue missed the consensus estimate of $1.0M by $39.0K. EPS beat the consensus estimate of $-0.52 by $0.00.

Compared to the same quarter a year prior, revenue declined 27.2% from $1.3M a year earlier and diluted EPS grew 62.6% from $-1.39.

You can read the 8-K earnings release (0001493152-26-023810) and the 10-Q periodic report (0001493152-26-023811) directly on SEC EDGAR. The filing index links above go to sec.gov.